Lantheus Holdings, Inc. · NASDAQ:LNTH
Lantheus — Q1 2025 Earnings Presentation
28 slides from Lantheus's earnings presentation, May 7, 2025
Slide 1: Lantheus First Quarter 2025 Results
Lantheus First Quarter 2025 Results May 7, 2025 © 2025 Lantheus. All rights reserved. 1
Slide 2: Agenda
Agenda SPEAKERS Highlights and Business Update Operational and Strategic Update Brian Markison Paul Blanchfield Amanda Morgan CEO President Chief Commercial Commercial Update Officer Development Pipeline Update Financial Update Closing Remarks Bob Marshall Mark Kinarney CFO and Treasurer Vice Presid
Slide 3: Safe Harbor Statements
Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe har
Slide 4: Agenda
Agenda SPEAKERS Highlights and Business Update Operational and Strategic Update Brian Markison Paul Blanchfield Amanda Morgan CEO President Chief Commercial Commercial Update Officer Development Pipeline Update Financial Update Closing Remarks Bob Marshall Mark Kinarney CFO and Treasurer Vice Presid
Slide 5: Building on our Foundation to Power the Future of Radiopharmaceuticals
Lantheus: Building on our Foundation to Power the Future of Radiopharmaceuticals Closed: APR 2025 Close: 2Q 20251 Close: by YE 20251 ACQUISITION ACQUISITION DIVESTMENT FOCUS 2025 Integrating Evergreen GROWTH ENGINE and Life Molecular Strong cash position 1 Imaging businesses and Disciplined capital
Slide 6: Agenda
Agenda SPEAKERS Highlights and Business Update Operational and Strategic Update Brian Markison Paul Blanchfield Amanda Morgan CEO President Chief Commercial Commercial Update Officer Development Pipeline Update Financial Update Closing Remarks Bob Marshall Mark Kinarney Q&A CFO and Treasurer Vice Pr
Slide 7: Recent Acquisitions Enhance Capabilities Across the Value Chain
Recent Acquisitions Enhance Capabilities Across the Value Chain Our acquisition of Evergreen STRENGTHEN our radiodiagnostic and therapeutic capabilities and upcoming acquisition of EXPAND our commercial portfolio and pipeline Life Molecular Imaging1 ENHANCE long-term growth potential • Scalable radi
Slide 8: Agenda
Agenda SPEAKERS Highlights and Business Update Operational and Strategic Update Brian Markison Paul Blanchfield Amanda Morgan CEO President Chief Commercial Commercial Update Officer Development Pipeline Update Financial Update Closing Remarks Bob Marshall Mark Kinarney Q&A CFO and Treasurer Vice Pr
Slide 9: #1 Utilized PSMA PET Imaging Agent
1Q 2025 #1Utilized $257.7M Well-positioned to maintain market PSMA PET 1Q 2025 Net Sales leadership and grow both volume and Imaging Agent1 revenue in 2025 Strategic partnerships secured with the vast majority of our business at key hospitals and free-standing imaging centers 1. Internal analyses an
Slide 10: PSMA PET Market May Exceed $3.5B by the End of the Decade
PSMA PET Market May Exceed $3.5B by the End of the Decade U.S. PSMA PET Imaging Annual Market & Scan Potential ~750K ANNUAL SCANS • Key growth drivers include: ~525K ~175K ANNUAL SCANS – Rising disease incidence and prevalence INITIAL STAGING – Conversion of conventional imaging in initial FOR SUSPE
Slide 11: #1 Utilized Ultrasound Enhancing Agent
#1 Utilized Ultrasound Enhancing Agent1 1Q 2025 $79.2M +3.5% Growth 1Q 2025 Net Sales 1Q 2025 Year-over-Year DEFINITY remains the #1 utilized ultrasound enhancing agent even with the return of competitive supply to the US market2 1. DRG Real World Data (RWD) report; 2. Internal analyses and data on
Slide 12: Agenda
Agenda SPEAKERS Highlights and Business Update Operational and Strategic Update Brian Markison Paul Blanchfield Amanda Morgan CEO President Chief Commercial Commercial Update Officer Development Pipeline Update Financial Update Closing Remarks Bob Marshall Mark Kinarney Q&A CFO and Treasurer Vice Pr
Slide 13: Expanding Pipeline of Radiopharmaceuticals
Innovation that Makes an Impact Lantheus Diagnostic Therapeutic Expanding Pipeline of Radiopharmaceuticals* LMI* Theranostic Diagnostic Candidate Target Isotope Indication/Disease Area Pre-Clinical Phase I Phase II Phase III Reg. Filing Prostate LNTH-24011 GRPR 68Ga Metastatic Prostate Cancer Cancer
Slide 14: Agenda
Agenda SPEAKERS Highlights and Business Update Operational and Strategic Update Brian Markison Paul Blanchfield Amanda Morgan CEO President Chief Commercial Commercial Update Officer Development Pipeline Update Financial Update Closing Remarks Bob Marshall Mark Kinarney CFO and Treasurer Vice Presid
Slide 15: Continued Strong Financial Performance in 1Q 2025
Continued Strong Financial Performance in 1Q 2025 Total Revenue USD Millions Other SPECT Strategic Partnerships & Other +$2.8 +0.8% TechneLite INCREASE $19.7 (-9.2%) DEFINITY $79.2 (+3.5%) $370.0 $372.8 PYLARIFY $257.7 (-0.5%) 1 2 1Q 2024 1Q 2025 1Q 2025 © 2025 Lantheus. All rights reserved. 15
Slide 16: Lantheus 1Q 2025 Financial Highlights
Lantheus 1Q 2025 Financial Highlights1 Adjusted EPS USD -$0.16 DECREASE -9.5% 1.69 1.53 1 1Q 2024 1Q 22025 Focused on Diversifying our Revenues and Setting up the Business for Continued Long-Term Growth 1. See slide 24 for a reconciliation of GAAP to non-GAAP financials; certain amounts may be subje
Slide 17: Growing Capital Resources Provide Financial Flexibility
Growing Capital Resources Provide Financial Flexibility1 Cash Flow Summary Free Cash Flow2 Resources USD Millions (1Q 2025) Three Months Ending March 31 2024 2025 Cash provided $127.2 $107.6 -$20.1 DECREASE $938.5M by operations CASH ON HAND3 Cash used in ($106.5) ($63.7) investing $119.0 $98.8 Cash
Slide 18: Updated FY 2025 Interim Corporate Financial Guidance
Updated FY 2025 Interim Corporate Financial Guidance1 Guidance Issued May 7, 2025 The Updated Interim Corporate Financial Guidance for the Full Year 2025 is as Follows: Prior Revenue $1.545B – $1.610B Current Revenue $1.550B – $1.585B FY 2025 Prior Adjusted Fully Diluted EPS2 $7.00 – $7.20 Current A
Slide 19: Agenda
Agenda SPEAKERS Highlights and Business Update Operational and Strategic Update Brian Markison Paul Blanchfield Amanda Morgan CEO President Chief Commercial Commercial Update Officer Development Pipeline Update Financial Update Closing Remarks Bob Marshall Mark Kinarney Q&A CFO and Treasurer Vice Pr
Slide 20: 1Q 2025 Key Takeaways
1Q 2025 Key Takeaways Building on our Foundation to Power Well positioned to lead next-generation PET imaging and the Future of Radiopharmaceuticals radiotherapeutics and deliver long-term sustainable growth Growth Drivers A diversified pipeline to support sustainable long-term growth #1 Utilized PS
Slide 21: Appendix
Appendix © 2025 Lantheus. All rights reserved. 21
Slide 22: Condensed Consolidated Statement of Operations – 1Q 2025
Condensed Consolidated Statement of Operations – 1Q 2025 © 2025 Lantheus. All rights reserved. 22
Slide 23: As Adjusted Condensed Consolidated Statement of Operations – 1Q 2025
As Adjusted Condensed Consolidated Statement of Operations – 1Q 2025 © 2025 Lantheus. All rights reserved. 23
Slide 24: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures (in thousands, except per share and percent data – unaudited) (a) The income tax effect of the adjustments between GAAP net income and adjusted net income (non-GAAP) takes into account the tax treatment and related tax rate that apply to each adj
Slide 25: Consolidated Statement of Operations
Consolidated Statement of Operations (in thousands, except per share data – unaudited) © 2025 Lantheus. All rights reserved. 25
Slide 26: Consolidated Segment Revenues Analysis
Consolidated Segment Revenues Analysis (in thousands – unaudited) © 2025 Lantheus. All rights reserved. 26
Slide 27: Reconciliation of Free Cash Flow
Reconciliation of Free Cash Flow (in thousands – unaudited) © 2025 Lantheus. All rights reserved. 27
Slide 28: Condensed Consolidated Balance Sheet
Condensed Consolidated Balance Sheet (in thousands – unaudited) © 2025 Lantheus. All rights reserved. 28